These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. The potential of trace amines and their receptors for treating neurological and psychiatric diseases. Berry MD Rev Recent Clin Trials; 2007 Jan; 2(1):3-19. PubMed ID: 18473983 [TBL] [Abstract][Full Text] [Related]
46. The emerging role of trace amine-associated receptor 1 in the functional regulation of monoamine transporters and dopaminergic activity. Miller GM J Neurochem; 2011 Jan; 116(2):164-76. PubMed ID: 21073468 [TBL] [Abstract][Full Text] [Related]
57. Discovery and In Vivo Efficacy of Trace Amine-Associated Receptor 1 (TAAR1) Agonist 4-(2-Aminoethyl)- Krasavin M; Peshkov AA; Lukin A; Komarova K; Vinogradova L; Smirnova D; Kanov EV; Kuvarzin SR; Murtazina RZ; Efimova EV; Gureev M; Onokhin K; Zakharov K; Gainetdinov RR Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232878 [TBL] [Abstract][Full Text] [Related]
58. Interaction Between the Trace Amine-Associated Receptor 1 and the Dopamine D Asif-Malik A; Hoener MC; Canales JJ Sci Rep; 2017 Oct; 7(1):13901. PubMed ID: 29066851 [TBL] [Abstract][Full Text] [Related]
59. The Case for TAAR1 as a Modulator of Central Nervous System Function. Rutigliano G; Accorroni A; Zucchi R Front Pharmacol; 2017; 8():987. PubMed ID: 29375386 [TBL] [Abstract][Full Text] [Related]
60. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Halff EF; Rutigliano G; Garcia-Hidalgo A; Howes OD Trends Neurosci; 2023 Jan; 46(1):60-74. PubMed ID: 36369028 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]